These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 32707096)

  • 1. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.
    Wang N; Zhan Y; Zhu L; Hou Z; Liu F; Song P; Qiu F; Wang X; Zou X; Wan D; Qian X; Wang S; Guo Y; Yu H; Cui M; Tong G; Xu Y; Zheng Z; Lu Y; Hong P
    Cell Host Microbe; 2020 Sep; 28(3):455-464.e2. PubMed ID: 32707096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience.
    Pereda R; González D; Rivero HB; Rivero JC; Pérez A; López LDR; Mezquia N; Venegas R; Betancourt JR; Domínguez RE
    J Interferon Cytokine Res; 2020 Sep; 40(9):438-442. PubMed ID: 32960147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quadruple therapy for asymptomatic COVID-19 infection patients.
    Wang L; Xu X; Ruan J; Lin S; Jiang J; Ye H
    Expert Rev Anti Infect Ther; 2020 Jul; 18(7):617-624. PubMed ID: 32362193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arbidol/IFN-α2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study.
    Xu P; Huang J; Fan Z; Huang W; Qi M; Lin X; Song W; Yi L
    Microbes Infect; 2020; 22(4-5):200-205. PubMed ID: 32445881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
    Davoudi-Monfared E; Rahmani H; Khalili H; Hajiabdolbaghi M; Salehi M; Abbasian L; Kazemzadeh H; Yekaninejad MS
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32661006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.
    Deng L; Li C; Zeng Q; Liu X; Li X; Zhang H; Hong Z; Xia J
    J Infect; 2020 Jul; 81(1):e1-e5. PubMed ID: 32171872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol.
    Zeng YM; Xu XL; He XQ; Tang SQ; Li Y; Huang YQ; Harypursat V; Chen YK
    Chin Med J (Engl); 2020 May; 133(9):1132-1134. PubMed ID: 32149772
    [No Abstract]   [Full Text] [Related]  

  • 9. Interferon-α2b Treatment for COVID-19.
    Zhou Q; Chen V; Shannon CP; Wei XS; Xiang X; Wang X; Wang ZH; Tebbutt SJ; Kollmann TR; Fish EN
    Front Immunol; 2020; 11():1061. PubMed ID: 32574262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics and drug therapies in patients with the common-type coronavirus disease 2019 in Hunan, China.
    Huang Q; Deng X; Li Y; Sun X; Chen Q; Xie M; Liu S; Qu H; Liu S; Wang L; He G; Gong Z
    Int J Clin Pharm; 2020 Jun; 42(3):837-845. PubMed ID: 32410206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study.
    Hao SR; Yan R; Zhang SY; Lian JS; Cai H; Zhang XL; Zheng L; Jia HY; Hu JH; Yu GD; Gu JQ; Ye CY; Jin CL; Lu YF; Xin JJ; Sheng JF; Yang YD
    J Zhejiang Univ Sci B; 2020 Aug.; 21(8):628-636. PubMed ID: 32748578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial.
    Dastan F; Nadji SA; Saffaei A; Marjani M; Moniri A; Jamaati H; Hashemian SM; Baghaei P; Abedini A; Varahram M; Yousefian S; Tabarsi P
    Int Immunopharmacol; 2020 Aug; 85():106688. PubMed ID: 32544867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
    Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study.
    Wang B; Li D; Liu T; Wang H; Luo F; Liu Y
    BMC Infect Dis; 2020 Oct; 20(1):723. PubMed ID: 33008327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.
    Yan D; Liu XY; Zhu YN; Huang L; Dan BT; Zhang GJ; Gao YH
    Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32430428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infection of severe acute respiratory syndrome coronavirus 2 in a patient with AIDS.
    Su J; Shen X; Ni Q; Zhao H; Cai J; Zhu B; Wu W; Lang G; Xu K; Sheng J
    AIDS; 2020 Aug; 34(10):1575-1576. PubMed ID: 32675569
    [No Abstract]   [Full Text] [Related]  

  • 18. BET 1: Lopinavir-ritonavir and COVID-19.
    Dolan D; Ingham J; Baombe J
    Emerg Med J; 2020 Jul; 37(7):450-451. PubMed ID: 32616658
    [No Abstract]   [Full Text] [Related]  

  • 19. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
    Cao B; Wang Y; Wen D; Liu W; Wang J; Fan G; Ruan L; Song B; Cai Y; Wei M; Li X; Xia J; Chen N; Xiang J; Yu T; Bai T; Xie X; Zhang L; Li C; Yuan Y; Chen H; Li H; Huang H; Tu S; Gong F; Liu Y; Wei Y; Dong C; Zhou F; Gu X; Xu J; Liu Z; Zhang Y; Li H; Shang L; Wang K; Li K; Zhou X; Dong X; Qu Z; Lu S; Hu X; Ruan S; Luo S; Wu J; Peng L; Cheng F; Pan L; Zou J; Jia C; Wang J; Liu X; Wang S; Wu X; Ge Q; He J; Zhan H; Qiu F; Guo L; Huang C; Jaki T; Hayden FG; Horby PW; Zhang D; Wang C
    N Engl J Med; 2020 May; 382(19):1787-1799. PubMed ID: 32187464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality.
    Fernández-Cruz A; Ruiz-Antorán B; Muñoz-Gómez A; Sancho-López A; Mills-Sánchez P; Centeno-Soto GA; Blanco-Alonso S; Javaloyes-Garachana L; Galán-Gómez A; Valencia-Alijo Á; Gómez-Irusta J; Payares-Herrera C; Morrás-Torre I; Sánchez-Chica E; Delgado-Téllez-de-Cepeda L; Callejas-Díaz A; Ramos-Martínez A; Múñez-Rubio E; Avendaño-Solá C
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.